| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H22N2O3 |
| Molecular Weight | 302.3682 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOCN1C(=O)NC(=O)C(C(C)C)=C1CC2=CC=CC=C2
InChI
InChIKey=MLILORUFDVLTSP-UHFFFAOYSA-N
InChI=1S/C17H22N2O3/c1-4-22-11-19-14(10-13-8-6-5-7-9-13)15(12(2)3)16(20)18-17(19)21/h5-9,12H,4,10-11H2,1-3H3,(H,18,20,21)
| Molecular Formula | C17H22N2O3 |
| Molecular Weight | 302.3682 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
MKC-442 (6-benzyl-1-(ethoxymethyl)-5-isopropyl-uracil) is a highly potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). Emivirine structurally is a nucleoside analog (NRTI) molecule, but it functions as a non-nucleoside reverse transcriptase inhibitor (NNRTI). Emivirine had reached phase 3 clinical trials for the treatment of HIV-1 infections before its further development was stopped.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 8.0 nM [IC50] |
PubMed
Patents
|
|
TARGET ORGANISM->INHIBITOR |
|
||
|
|
TARGET -> INHIBITOR |
|
Showing 1 to 2 of 2 entries
